Combinatorial effects of an epigenetic inhibitor and ionizing radiation contribute to targeted elimination of pancreatic cancer stem cell
Metrics: PDF 954 views | HTML 1770 views | ?
Hyun-Mi Kwon1,*, Eun-Jin Kang1,*, Keunsoo Kang2, Sung-Dae Kim1, Kwangmo Yang1 and Joo Mi Yi1
1Research Center, Dongnam Institute of Radiological & Medical Sciences (DIRAMS), Busan 46033, South Korea
2Department of Microbiology, Dankook Universty, Cheonan 31116, South Korea
*These authors have contributed equally to this work
Joo Mi Yi, email: firstname.lastname@example.org
Keywords: DNA methylation inhibitor, radiation, pancreatic cancer, cancer stem cell
Received: June 29, 2017 Accepted: August 27, 2017 Published: October 06, 2017
Pancreatic cancer is associated with a high mortality rate, owing to de novo and acquired drug resistance, thereby leading to highly invasive and metastatic pancreatic cancer cells. Therefore, targeting pancreatic cancer stem cells (CSCs) may be a novel therapeutic strategy for the treatment of pancreatic cancer. Here, we combined a DNA methylation inhibitor (5-aza-2’-deoxycytidine; 5-aza-dC) and ionizing radiation (IR) to improve anti-cancer effects by inhibiting growth and proliferation and promoting apoptosis of pancreatic cancer cells in vitro and in vivo. Importantly, the combinatorial effect of 5-aza-dC with IR on sphere-forming pancreatic cancer cells was preferentially targeted toward CSCs through the downregulation of regulatory factors of self-renewal and CSC surface markers. We next performed the RNA sequencing to understand the underlying cellular mechanisms of the combined treatment with IR and 5-aza-dC in pancreatic cancer cells. Global transcriptome profiling indicated that the expression of the Oct4-centered transcriptional network of genes was significantly downregulated in cells with combination treatment. Our data suggested that combination treatment with DNA methylation inhibitor and IR may be a novel therapeutic strategy for pancreatic cancer. Overall, these findings support the use of epigenetic therapy in combination with radiotherapy to improve therapeutic efficacy by targeting and eradicating pancreatic CSCs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.